J&J to Build Blood-Cancer Push With Controversial China Biotech

(Bloomberg) -- Johnson & Johnson is planning a new push into blood cancers that builds off a gene therapy it licensed from a Hong Kong-based company that has been awash in controversy.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.